Cassava Sciences Inc

SAVA

Equity

ISIN US14817C1071 / Valor 46983284

NASDAQ (2024-11-20)

USD 26.05-6.96%

Cassava Sciences Inc
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Cassava Sciences Inc is a biopharmaceutical company focused on the discovery and development of novel therapies for neurological diseases, particularly those affecting the brain. With a management and technical team boasting a rich history of drug development experience, including twelve FDA drug approvals in neuroscience and other clinical areas, Cassava Sciences is at the forefront of addressing some of the most challenging aspects of neurodegenerative diseases. The company's leadership, including Eric Schoen as Chief Financial Officer since 2018 and James W. Kupiec, M.D., who has served as Chief Clinical Development Officer and Chief Medical Officer, brings a wealth of experience from their previous roles in notable healthcare and pharmaceutical organizations. Their collective expertise spans across various disciplines crucial for drug development, such as preclinical and clinical development, medical affairs, regulatory affairs, pharmaceutical development, and supply chain management. This multidisciplinary approach underpins Cassava Sciences' commitment to advancing its pipeline of innovative treatments aimed at improving the lives of patients suffering from neurological conditions.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results ():

Summarized from source with an LLMView Source

Key figures

14.0%1Y

-51.0%3Y

1,951%5Y

Performance

108%1Y

102%3Y

146%5Y

Volatility